ETR:MOR - MorphoSys Stock Price, Price Target & More

€83.75 -2.30 (-2.67 %)
(As of 04/24/2018 04:00 PM ET)
Previous Close€83.75
Today's Range€83.50 - €86.25
52-Week Range€49.63 - €88.10
Volume66,273 shs
Average Volume153,687 shs
Market Capitalization$2.49 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About MorphoSys (ETR:MOR)

MorphoSys logoMorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase II clinical trials for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL-antibody directed against CD38, which is in Phase I/IIa trials for the treatment of multiple myeloma and various leukemias. The company's product pipeline also comprises MOR103, a human HuCAL-antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trials for treating rheumatoid arthritis; and MOR209/ES414, a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer that is in Phase I clinical trials for the treatment of metastatic castration-resistant prostate cancer. In addition, its product pipeline includes MOR106, a human monoclonal IL-17C antibody, which is in Phase I clinical trials for the treatment of atopic dermatitis; and MOR107, a novel lanthipeptide that is in Phase I clinical trials for the treatment of fibrotic diseases. MorphoSys AG has a regional licensing agreement with I-Mab to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao. The company was founded in 1992 and is headquartered in Planegg, Germany.

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolETR:MOR
CUSIPN/A
Phone+49-89-899270

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-159.62%
Return on Equity-25.28%
Return on Assets-22.11%

Miscellaneous

EmployeesN/A
Outstanding Shares29,010,000

How to Become a New Pot Stock Millionaire

MorphoSys (ETR:MOR) Frequently Asked Questions

What is MorphoSys' stock symbol?

MorphoSys trades on the ETR under the ticker symbol "MOR."

What price target have analysts set for MOR?

10 Wall Street analysts have issued 12 month price objectives for MorphoSys' stock. Their forecasts range from €57.00 to €100.00. On average, they expect MorphoSys' share price to reach €86.50 in the next twelve months. View Analyst Ratings for MorphoSys.

Who are MorphoSys' key executives?

MorphoSys' management team includes the folowing people:
  • Dr. Simon E. Moroney Ph.D., Chairman of Management Board and Chief Exec. Officer
  • Mr. Jens H. Holstein, Chief Financial Officer and Member of Management Board
  • Dr. Marlies Sproll, Special Adviser to the Chief Exec. Officer (Age 60)
  • Dr. Malte Peters, Chief Devel. Officer and Member of Management Board (Age 56)
  • Mr. Klaus De Wall, Head of Accounting & Tax

Has MorphoSys been receiving favorable news coverage?

Media coverage about MOR stock has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MorphoSys earned a coverage optimism score of 0.22 on Accern's scale. They also gave headlines about the company an impact score of 45.78 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately €83.75.

How big of a company is MorphoSys?

MorphoSys has a market capitalization of $2.49 billion.

How can I contact MorphoSys?

MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.


MarketBeat Community Rating for MorphoSys (MOR)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  208
MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote "Outperform" if you believe MOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

MorphoSys (ETR:MOR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for MorphoSys in the last 12 months. Their average twelve-month price target is €86.50The high price target for MOR is €100.00 and the low price target for MOR is €57.00. There are currently 2 sell ratings, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.632.86
Ratings Breakdown: 2 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: €86.50€86.52€84.38€81.86

MorphoSys (ETR:MOR) Consensus Price Target History

Price Target History for MorphoSys (ETR:MOR)

MorphoSys (ETR:MOR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/18/2018CommerzbankSet Price TargetBuy€98.00View Rating Details
4/9/2018Bryan, Garnier & CoSet Price TargetBuy€91.00View Rating Details
3/14/2018Oddo BhfSet Price TargetBuy€93.00View Rating Details
3/14/2018Goldman SachsSet Price TargetNeutral€86.00View Rating Details
3/13/2018Independent ResearchSet Price TargetBuy€97.00View Rating Details
3/13/2018Berenberg BankSet Price TargetBuy€85.00View Rating Details
3/13/2018Royal Bank of CanadaSet Price TargetSell€57.00View Rating Details
3/13/2018JPMorgan ChaseReiterated RatingBuyView Rating Details
3/12/2018Deutsche BankSet Price TargetBuy€94.00View Rating Details
1/19/2018HSBCSet Price TargetSell€64.00View Rating Details
(Data available from 4/24/2016 forward)

Earnings

Dividends

MorphoSys (ETR:MOR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

MorphoSys (ETR MOR) Insider Trading and Institutional Ownership History

Insider Trading History for MorphoSys (ETR:MOR)

MorphoSys (ETR MOR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

MorphoSys (ETR MOR) News Headlines

Source:
DateHeadline
BRIEF-Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 MillionBRIEF-Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million
www.reuters.com - April 24 at 10:08 AM
IPO News This Week: DocuSign Tops List of 6 Scheduled OfferingsIPO News This Week: DocuSign Tops List of 6 Scheduled Offerings
www.msn.com - April 22 at 4:20 PM
MorphoSys AG (MOR) IPO Opens Modestly HigherMorphoSys AG (MOR) IPO Opens Modestly Higher
www.streetinsider.com - April 20 at 10:31 AM
Cancer biotech MorphoSys prices $208 million US offering at $25.04Cancer biotech MorphoSys prices $208 million US offering at $25.04
www.nasdaq.com - April 19 at 10:15 AM
BRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On NasdaqBRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq
www.reuters.com - April 19 at 10:15 AM
BRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADSBRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADS
www.reuters.com - April 18 at 10:22 AM
MorphoSys (MOR) Given a €98.00 Price Target by Commerzbank AnalystsMorphoSys (MOR) Given a €98.00 Price Target by Commerzbank Analysts
www.americanbankingnews.com - April 18 at 10:13 AM
MorphoSys (MOR) Given Average Rating of "Hold" by BrokeragesMorphoSys (MOR) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 18 at 9:40 AM
Goldman Sachs Reiterates €55.00 Price Target for MorphoSys (MOR)Goldman Sachs Reiterates €55.00 Price Target for MorphoSys (MOR)
www.americanbankingnews.com - April 18 at 12:34 AM
MorphoSys (MOR) PT Set at €55.00 by Goldman SachsMorphoSys (MOR) PT Set at €55.00 by Goldman Sachs
www.americanbankingnews.com - April 16 at 10:54 PM
Commerzbank Reiterates "€76.00" Price Target for MorphoSys (MOR)Commerzbank Reiterates "€76.00" Price Target for MorphoSys (MOR)
www.americanbankingnews.com - April 16 at 10:54 PM
MorphoSys (MOR) PT Set at €90.00 by Deutsche BankMorphoSys (MOR) PT Set at €90.00 by Deutsche Bank
www.americanbankingnews.com - April 14 at 3:38 PM
MorphoSys (MOR) Given a €68.00 Price Target by Berenberg Bank AnalystsMorphoSys (MOR) Given a €68.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - April 13 at 9:58 PM
MorphoSys Finalizes U.S. IPO TermsMorphoSys Finalizes U.S. IPO Terms
seekingalpha.com - April 13 at 3:51 PM
Deutsche Bank Analysts Give MorphoSys (MOR) a €90.00 Price TargetDeutsche Bank Analysts Give MorphoSys (MOR) a €90.00 Price Target
www.americanbankingnews.com - April 13 at 9:59 AM
MorphoSys AG: MorphoSys Nominates New Candidates for Supervisory BoardMorphoSys AG: MorphoSys Nominates New Candidates for Supervisory Board
www.finanznachrichten.de - April 10 at 3:50 PM
MorphoSys Nominates New Candidates for Supervisory BoardMorphoSys Nominates New Candidates for Supervisory Board
finance.yahoo.com - April 10 at 10:39 AM
BRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC FilingBRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing
www.reuters.com - April 9 at 10:30 AM
Bryan, Garnier & Co Analysts Give MorphoSys (MOR) a €91.00 Price TargetBryan, Garnier & Co Analysts Give MorphoSys (MOR) a €91.00 Price Target
www.americanbankingnews.com - April 9 at 7:31 AM
MorphoSys (MOR) PT Set at €81.00 by Oddo BhfMorphoSys (MOR) PT Set at €81.00 by Oddo Bhf
www.americanbankingnews.com - April 8 at 9:10 PM
BRIEF-Morphosys Says Tremfya Approved To Treat Psoriasis In JapanBRIEF-Morphosys Says Tremfya Approved To Treat Psoriasis In Japan
www.reuters.com - April 6 at 10:58 AM
Commerzbank Analysts Give MorphoSys (MOR) a €76.00 Price TargetCommerzbank Analysts Give MorphoSys (MOR) a €76.00 Price Target
www.americanbankingnews.com - April 5 at 7:58 PM
MorphoSys Announces Approvals for Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Brazil and AustraliaMorphoSys Announces Approvals for Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque Psoriasis in Brazil and Australia
finance.yahoo.com - April 5 at 3:50 PM
Goldman Sachs Analysts Give MorphoSys (MOR) a €72.00 Price TargetGoldman Sachs Analysts Give MorphoSys (MOR) a €72.00 Price Target
www.americanbankingnews.com - April 5 at 3:30 PM
MorphoSys (MOR) Given a €76.00 Price Target at CommerzbankMorphoSys (MOR) Given a €76.00 Price Target at Commerzbank
www.americanbankingnews.com - April 1 at 5:22 PM
Independent Research Reiterates €93.00 Price Target for MorphoSys (MOR)Independent Research Reiterates €93.00 Price Target for MorphoSys (MOR)
www.americanbankingnews.com - April 1 at 3:42 PM
MorphoSys (MOR) Given a €85.00 Price Target by JPMorgan Chase AnalystsMorphoSys (MOR) Given a €85.00 Price Target by JPMorgan Chase Analysts
www.americanbankingnews.com - April 1 at 1:36 PM
MorphoSys (MOR) PT Set at €72.00 by Goldman SachsMorphoSys (MOR) PT Set at €72.00 by Goldman Sachs
www.americanbankingnews.com - April 1 at 12:24 PM
MorphoSys (MOR) Given a €90.00 Price Target by Oddo Bhf AnalystsMorphoSys (MOR) Given a €90.00 Price Target by Oddo Bhf Analysts
www.americanbankingnews.com - April 1 at 9:41 AM
MorphoSys (MOR) Given a €97.00 Price Target by JPMorgan Chase & Co. AnalystsMorphoSys (MOR) Given a €97.00 Price Target by JPMorgan Chase & Co. Analysts
www.americanbankingnews.com - March 30 at 8:24 PM
MorphoSys AG (MOR) Receives Consensus Rating of "Hold" from BrokeragesMorphoSys AG (MOR) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 24 at 9:57 AM
BRIEF-Morphosys AG Says ‍Files Registration Statement In United States For A Proposed American Depositary Shares (ADS) OfferingBRIEF-Morphosys AG Says ‍Files Registration Statement In United States For A Proposed American Depositary Shares (ADS) Offering
www.reuters.com - March 22 at 3:46 PM
MorphoSys AG: MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) OfferingMorphoSys AG: MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering
www.finanznachrichten.de - March 22 at 3:46 PM
MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) OfferingMorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering
finance.yahoo.com - March 22 at 3:46 PM
Commerzbank Analysts Give MorphoSys (MOR) a €98.00 Price TargetCommerzbank Analysts Give MorphoSys (MOR) a €98.00 Price Target
www.americanbankingnews.com - March 19 at 10:06 PM
MorphoSys (MOR) Given a €85.00 Price Target by Berenberg Bank AnalystsMorphoSys (MOR) Given a €85.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - March 18 at 11:54 AM
MorphoSys (MOR) PT Set at €57.00 by Royal Bank of CanadaMorphoSys (MOR) PT Set at €57.00 by Royal Bank of Canada
www.americanbankingnews.com - March 18 at 11:52 AM
MorphoSys (MOR) Given a €86.00 Price Target at Goldman SachsMorphoSys (MOR) Given a €86.00 Price Target at Goldman Sachs
www.americanbankingnews.com - March 18 at 11:16 AM
MorphoSys AG: Clinical Data Presentations at AAT in Alzheimers DiseaseMorphoSys AG: Clinical Data Presentations at AAT in Alzheimer's Disease
www.finanznachrichten.de - March 14 at 4:40 PM
Clinical Data Presentations at AAT in Alzheimers DiseaseClinical Data Presentations at AAT in Alzheimer's Disease
finance.yahoo.com - March 14 at 4:40 PM
MorphoSys (MOR) Given a €91.20 Price Target at Bryan, Garnier & CoMorphoSys (MOR) Given a €91.20 Price Target at Bryan, Garnier & Co
www.americanbankingnews.com - March 14 at 4:12 PM
MorphoSys (MOR) PT Set at €93.00 by Oddo BhfMorphoSys (MOR) PT Set at €93.00 by Oddo Bhf
www.americanbankingnews.com - March 14 at 2:47 PM
Independent Research Analysts Give MorphoSys (MOR) a €97.00 Price TargetIndependent Research Analysts Give MorphoSys (MOR) a €97.00 Price Target
www.americanbankingnews.com - March 13 at 3:47 PM
MorphoSys AG: MorphoSys Presents Results for Fiscal Year 2017MorphoSys AG: MorphoSys Presents Results for Fiscal Year 2017
www.finanznachrichten.de - March 13 at 10:59 AM
MorphoSys AG 2017 Q4 - Results - Earnings Call SlidesMorphoSys AG 2017 Q4 - Results - Earnings Call Slides
seekingalpha.com - March 13 at 10:59 AM
MorphoSys (MOR) Rating Reiterated by JPMorgan Chase & Co.MorphoSys (MOR) Rating Reiterated by JPMorgan Chase & Co.
www.americanbankingnews.com - March 13 at 7:42 AM
Deutsche Bank Analysts Give MorphoSys (MOR) a €94.00 Price TargetDeutsche Bank Analysts Give MorphoSys (MOR) a €94.00 Price Target
www.americanbankingnews.com - March 12 at 9:02 AM
MorphoSys (MOR) Given a €86.00 Price Target by Goldman Sachs Group AnalystsMorphoSys (MOR) Given a €86.00 Price Target by Goldman Sachs Group Analysts
www.americanbankingnews.com - March 11 at 2:35 PM
MorphoSys AG (MOR) Given Average Recommendation of "Hold" by AnalystsMorphoSys AG (MOR) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - February 27 at 12:08 PM
Oddo Bhf Reiterates "€90.00" Price Target for MorphoSys (MOR)Oddo Bhf Reiterates "€90.00" Price Target for MorphoSys (MOR)
www.americanbankingnews.com - February 20 at 4:52 PM

SEC Filings

MorphoSys (ETR:MOR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

MorphoSys (ETR MOR) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.